

*For Health Professionals Who Care for People with Cancer*

## Inside This Issue:

### Editor's Choice

#### New Programs

- **LYMCIV** Venetoclax and Ibrutinib for Treatment of Relapsed/Refractory Mantle Cell Lymphoma
- **MYDBLDFTI** Daratumumab, Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated, Transplant-Ineligible Multiple Myeloma

#### Drug Update

Implementation of Subcutaneous Nivolumab  
Ivosidenib Alert Card

#### Cancer Drug Manual®

**Revised** alectinib, atezolizumab, carmustine, enzalutamide, ivosidenib, nivolumab, venetoclax

**Chemotherapy Preparation and Stability Chart** ifosfamide, paclitaxel NAB, pertuzumab

**CDM Editorial Board Changes**

### Benefit Drug List

**New** LYMCIV, MYDBLDFTI, bendamustine (LKNOS, LYNOS)

**Revised** MYDBLDFTE

### Protocols, PPOs and Patient Handouts

**New LY** LYMCIV **MY** MYDBLDFTI

**Revised BR** UBRAJABEAI, UBRAJABET, BRAJLHRHAI, BRAJLHRHT, UBRAVCAFLV, BRAVLHRHAI, BRAVLHRHT, BRAVPALAI, BRAVPBFLV, BRAVRBFLV, BRAVRIBAI **GI** GIAJNIV, GIAVPEM, GIAVPEM6, GIGAVCOXN, GIGAVCOXP, GIGAVFFOXN, GIGAVFFOXP **GU** UGUAJNIV, UGUAJNIV4, GUAVIPNI, GUAVNIV, GUAVNIV4, GUAVNIVC, GUAVNIVC4, GUMCSPABI, GUMCSPAPA, GUMCSPDAR, GUMCSPENZ, GUPDOC, GUPDOCADT, UGUPOLAP **HN** HNAVNIV, HNAVNIV4, HNNLAPRT **LK** ULKAMLAVEN, ULKAMLAZIV **LU** LUAJALE, LUVALE, LUAVNIV, LUAVNIV4, ULUAVPPAF, ULUAVPPAMI, LULAPE2RT, LULAPERT, LUNANIVPC, LUNANIVPP **LY** LYCLLIV, LYIVACR, LYMIBRU **MY** MYBSD, MYDBLDFTE, UMYTEC **SA** SANADENO **SM** SMAJNIV, SMAJNIV4, SMAVALIPNI, SMAVIPNI, SMAVNIV, SMAVNIV4

### Resources and Contact Information

## Editor's Choice

### New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 July 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

#### Lymphoma

**Venetoclax and Ibrutinib for Treatment of Relapsed/Refractory Mantle Cell Lymphoma (LYMCIV)** – The BC Cancer Lymphoma Tumour Group is implementing combination therapy with ibrutinib and venetoclax in patients with relapsed or refractory mantle cell lymphoma (MCL).

The double blind, randomized phase III SYMPATICO trial compared ibrutinib-venetoclax with ibrutinib-placebo in patients with MCL who had received at least one prior treatment regimen.<sup>1,2</sup> Combination treatment improved median progression free survival (PFS) and complete response (CR) rate. The safety profile of the combination was consistent with the known adverse effect profiles of the individual drugs; grade 3-4 neutropenia and thrombocytopenia occurred more frequently in the ibrutinib-venetoclax group.

## Editor's Choice

### Myeloma

**Daratumumab, Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated, Transplant-Ineligible Multiple Myeloma (MYDBLDFTI)** – The BC Cancer Myeloma Tumour Group is implementing quadruplet therapy with daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the first-line treatment of patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant. Treatment is continued until disease progression (bortezomib for first 8 cycles only to limit long-term toxicity). Note that the protocol code MYDBLDFTI introduces the suffix **TI** to denote “transplant-ineligible”. The treatment protocol for daratumumab plus VRd in the transplant-eligible population was implemented May 2026; the protocol code has now been revised from MYDBLDF to MYDBLDF**TE** where the suffix **TE** denotes “transplant-eligible”.

In the randomized, active-controlled phase III CEPHEUS trial, daratumumab, when added to VRd, demonstrated significantly higher rates of PFS, CR and minimal residual disease (MRD)-negativity in untreated, transplant-ineligible patients with multiple myeloma.<sup>3,4</sup> The safety profile of the daratumumab-VRd regimen was consistent with the expected adverse effects of the individual agents.

#### References:

1. Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre randomized, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2025;26:200-213. [https://doi.org/10.1016/S1470-2045\(24\)00682-X](https://doi.org/10.1016/S1470-2045(24)00682-X)
2. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Venetoclax (Venclexta®). *Canadian Journal of Health Technologies* 2025;5(10):1-26. <https://doi.org/10.51731/cjht.2025.1245>
3. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. *Nat Med* 2025;31(4):1195-1202. <https://doi.org/10.1038/s41591-024-03485-7>
4. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Daratumumab (Darzalex® SC). *Canadian Journal of Health Technologies* 2026;6(3):1-15. <https://doi.org/10.51731/cjht.2026.1388>

## Drug Update

### Implementation of Subcutaneous Nivolumab

Effective 01 July 2026, subcutaneous (SC) nivolumab is being implemented as an option in several nivolumab-containing treatment protocols. Eligible protocols reflect Health Canada-approved indications for SC nivolumab. The *Revised Protocols, PPPOs and Patient Handouts* table at the end of this issue highlights updated protocols.

#### Dosing and Treatment Protocols

Patients initiated on nivolumab may receive SC nivolumab starting from the first dose. Patients who have already started IV nivolumab treatment may receive subsequent doses administered as the SC injection.

Within a treatment protocol, both the IV and SC options follow the same treatment interval. Subcutaneous nivolumab is delivered as a fixed dose, based on the treatment interval:

Treatment interval	IV nivolumab dose		SC nivolumab dose	SC injection volume
Every 2 weeks	3 mg/kg	max 240 mg	600 mg	5 mL
Every 3 weeks	4.5 mg/kg	max 360 mg	900 mg	7.5 mL
Every 4 weeks	6 mg/kg	max 480 mg	1200 mg	10 mL

## Drug Update

Some treatment protocols use nivolumab concomitantly with ipilimumab in the induction phase, followed by nivolumab monotherapy in the maintenance phase. For these protocols, IV nivolumab will continue to be used in the induction phase; upon starting the maintenance phase, nivolumab IV or SC may be used.

### Subcutaneous Formulation Characteristics

Subcutaneous nivolumab is formulated with the enzyme hyaluronidase. Hyaluronidase transiently degrades hyaluronan (also known as hyaluronic acid), a component of the extracellular matrix in the subcutaneous space. This increases the permeability of the subcutaneous tissue, expanding the injection space to allow the dispersion and absorption of 10 mL of nivolumab. Hyaluronidase may increase the systemic absorption of other drugs administered near the injection site for 24-48 hours; therefore, other subcutaneous drugs should be administered at other sites whenever possible.

### Administration-Related Reactions

Subcutaneous nivolumab is administered as a single injection into the abdomen or thigh over 3-5 minutes. Local injection site reactions occur in approximately 7% of patients and are typically low grade and resolve without treatment. Systemic administration-related reactions – commonly referred to as infusion-related reactions or hypersensitivity reactions – may occur with IV or SC nivolumab. Systemic reactions with SC nivolumab have been reported in less than 1% of patients, compared with approximately 3% of patients with IV nivolumab.

#### References:

1. Bristol-Myers Squibb Canada. OPDIVO® SC product monograph. Montreal, Quebec; February 6, 2026
2. Bristol-Myers Squibb Canada. OPDIVO® product monograph. St-Laurent, Quebec; June 19, 2025.
3. Albiges L, Bourlon MT, Chacón M, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. *Ann Oncol* 2025;36(1):99-107. <https://doi.org/10.1016/j.annonc.2024.09.002>

## Ivosidenib Alert Card

An **alert card** for the **risk of differentiation syndrome** has been developed for patients receiving **ivosidenib**. The alert card can be found in the [Cancer Drug Manual](#)® Drug Index.

## Cancer Drug Manual<sup>©</sup>

All documents are available in the [Cancer Drug Manual](#)® on the BC Cancer website.

## Revised Documents

### Alectinib Monograph and Patient Handout

*Side Effects* table: added pancreatitis and hypertriglyceridemia

*Side Effects* paragraphs: added paragraph on hypertriglyceridemia and pancreatitis

#### **Patient Handout:**

*Side Effects* table: added triglycerides bullet

*Check with your healthcare team* bullets: added 'severe' to sudden abdominal pain

*Throughout:* updated wording per current template

### Atezolizumab Monograph

*Common Trade Names:* updated with SC brand name

*Supply and Storage:* added brand names

*Dosage Guidelines:* added SC brand name to footer

### Carmustine Monograph and Chemotherapy Preparation and Stability Chart

*Supply and Storage:* deleted Marcan ready-to-use vials (discontinued)

**Chemotherapy Preparation and Stability Chart:** deleted entry for Marcan ready-to-use vials

### Enzalutamide Monograph and Patient Handout

*Side Effects* table: added dysphagia and incidence for alopecia

*Supply and Storage:* updated with Auro brand (generic)

*Additional information:* updated information about blister card packaging

*Dosage Guidelines:* updated with information to swallow with sufficient water

**Patient Handout:** updated administration bullet with instruction to use plenty of water

### Ivosidenib Patient Handout

*Bulleted section (first page):* added information related to patient alert card

### Nivolumab Monograph, IV & SC Patient Handouts and Chemotherapy Preparation and Stability Chart

*Common Trade Names:* updated with SC brand name

*Special Precautions > Caution* bullet: clarified sodium content applies to IV formulation

*Side Effects* table: added injection site reactions following SC administration

*Supply and Storage:* added brand name to existing IV formulation; updated with SC formulation

*Additional information:* section added, including information about hyaluronidase and vial overfill

*Parenteral Administration:* added information for SC route; clarified intermittent infusion route

*Dosage Guidelines:* added subcutaneous dosing information

**IV Patient Handout: Header/Footer & Banner bar:** revised from “nivolumab” to “nivolumab IV injection”

**SC Patient Handout: NEW** (adapted nivolumab patient handout for the SC route)

**Chemotherapy Preparation and Stability Chart:** added entry for SC nivolumab formulation

### Venetoclax Monograph

*Uses:* moved non-Hodgkin lymphoma to *Primary uses*; added mantle cell lymphoma (MCL) throughout monograph as appropriate

*Dosage Guidelines:* added new BC Cancer protocol LYMCIV

## Chemotherapy Preparation and Stability Chart

### Ifosfamide

added new brand (Qilu China) (temporarily imported for drug shortage)

### Paclitaxel NAB

added new brand (BMS USA) (temporarily imported for drug shortage)

### Pertuzumab

*Product column:* added ½NS

## CDM Editorial Board Changes

The Cancer Drug Manual<sup>®</sup> Editorial Review Board would like to welcome **Nancy Oun** as the incoming editor of the Cancer Drug Manual<sup>®</sup>. Nancy joins Provincial Pharmacy from BC Cancer Surrey Centre, where she worked as a clinical pharmacist since 2021.

In memoriam of **Dr. Jean-Michel Lavoie**, a valued contributor and physician member of the CDM Editorial Board for the past four years. The CDM Board appreciates his passion and dedication to his work and his patients, and for bringing his expertise and attention to detail to the Cancer Drug Manual<sup>®</sup>.

## Benefit Drug List

### New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 July 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Relapsed/Refractory Mantle Cell Lymphoma using <b>Venetoclax</b> and <b>Ibrutinib</b>	<b>LYMCIV</b>	Class I
Treatment of Previously Untreated Multiple Myeloma Ineligible for Stem Cell Transplant using <b>Daratumumab</b> , <b>Bortezomib</b> , <b>Lenalidomide</b> and <b>Dexamethasone</b>	<b>MYDBLDFTI</b>	Class I
<b>bendamustine</b> : lymphodepletion prior to CAR-T cell therapy	<b>LKNOS</b>	Class I
<b>bendamustine</b> : lymphodepletion prior to CAR-T cell therapy	<b>LYNOS</b>	Class I

### Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 July 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Previously Untreated Multiple Myeloma and Eligible for Stem Cell Transplant using <b>Daratumumab</b> , <b>Bortezomib</b> , <b>Lenalidomide</b> and <b>Dexamethasone</b> ➤ Protocol code revised: <b>MYDBLDF</b> → <b>MYDBLDFTE</b>	<b>MYDBLDFTE</b>	Class I

## Highlights of New & Revised Protocols, PPPOs and Patient Handouts

**BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYMCIV	Treatment of Relapsed/Refractory Mantle Cell Lymphoma using Venetoclax and Ibrutinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 3 x PPPOs	<input type="checkbox"/>
MYDBLDFTI	Treatment of Previously Untreated Multiple Myeloma Ineligible for Stem Cell Transplant using Daratumumab, Bortezomib, Lenalidomide and Dexamethasone	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 2 x PPPOs	<input type="checkbox"/>

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
UBRAJABEAI	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor with or without LHRH Agonist	<i>Tests and contact information updated</i>	<i>Tests updated</i>	---
UBRAJABET	Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen with or without LHRH Agonist	<i>Tests and contact information updated</i>	<i>Tests updated; treatment clarified</i>	---
BRAJLHRHAI	Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or in Men with High-Risk Early Stage Breast Cancer	<i>Tests and contact information updated</i>	<i>Tests updated</i>	---
BRAJLHRHT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using a LHRH Agonist and Tamoxifen	<i>Tests and contact information updated; eligibility and exclusions clarified</i>	<i>Tests updated</i>	---
UBRAVCAFLV	Therapy of Advanced Breast Cancer using Capiwasertib and Fulvestrant with or without LHRH Agonist	<i>Tests and contact information updated; dose modifications clarified</i>	<i>Tests updated</i>	---
BRAVLHRHAI	Therapy for Advanced Breast Cancer using a LHRH Agonist and an Aromatase Inhibitor	<i>Tests and contact information updated</i>	<i>Tests updated</i>	---
BRAVLHRHT	Palliative Therapy for Breast Cancer using a LHRH Agonist and Tamoxifen	<i>Tests and contact information updated; eligibility and exclusions clarified</i>	<i>Tests updated</i>	---

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVPALAI</b>	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist	<i>Tests and contact information updated</i>	<i>Tests updated</i>	---
<b>BRAVPBFLV</b>	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	<i>Tests and contact information updated; dose modifications clarified</i>	<i>Tests updated</i>	---
<b>BRAVRBFLV</b>	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	<i>Tests and contact information updated; dose modifications clarified</i>	<i>Tests updated</i>	---
<b>BRAVRIBAI</b>	Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with or without LHRH Agonist	<i>Tests and contact information updated</i>	<i>Tests updated</i>	---
<b>GI   Gastrointestinal</b>				
<b>GIAJNIV</b>	Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer using Nivolumab	<i>Nivolumab SC option added; precautions updated; contact information clarified</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; treatment, side effects and contact info updated</i>
<b>GIAVPEM</b>	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab	---	---	<i>Serious side effects table corrected; medical alert card, letter and contact info updated</i>
<b>GIAVPEM6</b>	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab	---	---	
<b>GIGAVCOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>Nivolumab SC option added; precautions updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; treatment, instructions, side effects and contact info updated</i>
<b>GIGAVCOXP</b>	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	---	---	<i>Serious side effects table corrected; medical alert card, letter and contact info updated</i>
<b>GIGAVFFOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	<i>Nivolumab SC option added; precautions updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; instructions, side effects, treatment and contact info updated</i>

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GIGAVFFOXP</b>	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	---	---	<i>Serious side effects table corrected; medical alert card, letter and contact info updated</i>
<b>GU   Genitourinary</b>				
<b>UGUAJNIV</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>UGUAJNIV4</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>GUAVIPNI</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<b>Maintenance PPPO</b> <i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>GUAVNIV</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>GUAVNIV4</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>GUAVNIVC</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab and Cabozantinib	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	---
<b>GUAVNIVC4</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab and Cabozantinib	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	---
<b>GUMCSPABI</b>	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	<i>Eligibility updated</i>	---	---
<b>GUMCSPAPA</b>	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Apalutamide	<i>Eligibility updated</i>	---	---
<b>GUMCSPDAR</b>	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Darolutamide	<i>Eligibility updated</i>	---	---
<b>GUMCSPENZ</b>	Treatment for Metastatic Castration-Sensitive Prostate Cancer using Enzalutamide	<i>Eligibility updated</i>	---	---

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GUPDOC</b>	Palliative Therapy for Metastatic Hormone Refractory Prostate Cancer using Docetaxel and Prednisone	<i>Contact information and bag size updated; eligibility, tests and units of measure clarified</i>	<i>Bag size updated; tests, treatment and units of measure clarified</i>	---
<b>GUPDOCADT</b>	First-Line Treatment of Castration-Sensitive, Metastatic Prostate Cancer using Docetaxel and Androgen Deprivation Therapy	<i>Contact information and bag size updated; eligibility, tests and units of measure clarified</i>	<i>Bag size updated; tests and units of measure clarified</i>	---
<b>UGUPOLAP</b>	Treatment of Metastatic Castration-Resistant Prostate Cancer using Olaparib	---	<i>Tests corrected</i>	---
<b>HN   Head and Neck</b>				
<b>HNAVNIV</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>HNAVNIV4</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	
<b>HNNLAPRT</b>	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation	<i>Tests updated; units of measure clarified; physician contact information updated</i>	<i>Number of cycles clarified; return appointment orders updated; units of measure clarified</i>	---
<b>LK   Leukemia and BMT</b>				
<b>ULKAMLAVEN</b>	Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	<i>Antimicrobial guidance updated; drug interactions table modified; contact information updated</i>	---	---
<b>ULKAMLAZIV</b>	Therapy of Acute Myeloid Leukemia using Azacitidine and Ivosidenib	<i>Alert card comment and antimicrobial guidance updated; contact information updated</i>	<i>Alert card comment updated</i>	---
<b>LU   Lung</b>				
<b>LUAJALE</b>	Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer with Alectinib	<i>Tests, dose modifications and precautions updated</i>	<i>Tests updated</i>	---
<b>LUAVALE</b>	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib	<i>Tests, dose modifications and precautions updated</i>	<i>Tests updated</i>	<i>Side effects updated</i>

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LUAVNIV</b>	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, treatment and contact info updated</i>
<b>LUAVNIV4</b>	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions updated</i>	<i>Nivolumab SC option added</i>	
<b>ULUAVPPAF</b>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Carboplatin, Pemetrexed and Amivantamab	---	<b>2 x PPPOs</b> <i>Premedications updated</i>	---
<b>ULUAVPPAMI</b>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Carboplatin, Pemetrexed and Amivantamab	---	<b>2 x PPPOs</b> <i>Premedications updated</i>	---
<b>LULAPE2RT</b>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Alternative Dosing of Cisplatin and Etoposide with Radiation Therapy	<i>Antibiotic prophylaxis removed; renal dysfunction section updated; units of measure clarified; physician contact information updated</i>	---	---
<b>LULAPERT</b>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy	<i>Antibiotic prophylaxis removed; renal dysfunction section updated; units of measure clarified; physician contact information updated</i>	---	---
<b>LUNANIVPC</b>	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, Carboplatin and Paclitaxel	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	---
<b>LUNANIVPP</b>	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	---
<b>LUOTPERT</b>	Treatment of Thymoma using Cisplatin and Etoposide with Radiation Therapy	<i>Antibiotic prophylaxis removed; renal dysfunction section updated; units of measure clarified; physician contact information updated</i>	---	---
<b>LUSCPEPORT</b>	Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	<i>Antibiotic prophylaxis removed; renal dysfunction section updated; units of measure clarified; physician contact information updated</i>	---	---

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LUSCPERT</b>	Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy	<i>Antibiotic prophylaxis removed; renal dysfunction section updated; units of measure clarified; physician contact information updated</i>	---	---
<b>LY   Lymphoma</b>				
<b>LYCLLIV</b>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Ibrutinib and Venetoclax	<i>Contact information and dose modifications updated</i>	<b>Cycle 4 PPPOs and Cycles 5-15 PPPO Prechemo metrics updated</b>	---
<b>LYIVACR</b>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	<i>Dexamethasone eye drops added; physician contact information updated</i>	---	---
<b>LYMIBRU</b>	Treatment of Relapsed/Refractory Mantle-Cell Lymphoma using Ibrutinib	<i>Contact information updated; eligibility note added</i>	---	---
<b>MY   Myeloma</b>				
<b>MYBSD</b>	Treatment of Multiple Myeloma using Bortezomib, Selinexor and Dexamethasone with or without Cyclophosphamide	<i>Tests section updated</i>	---	---
<b>MYDBLDFTE</b>	Treatment of Previously Untreated Multiple Myeloma and Eligible for Stem Cell Transplant using Daratumumab, Bortezomib, Lenalidomide and Dexamethasone	<i>Protocol code revised (TE = transplant-eligible)</i>	<b>4 x PPPOs Protocol code revised (TE = transplant-eligible)</b>	---
<b>UMYTEC</b>	Treatment of Relapsed and Refractory Multiple Myeloma using Teclistamab	---	<b>Cycle 2+ PPPO CRS/ICANS prechemo metric removed</b>	---
<b>SA   Sarcoma</b>				
<b>SANADENO</b>	Denosumab for Neoadjuvant Use in Patients with Non-Metastatic Operable Giant Cell Tumour of the Bone	---	<i>Return appointment orders updated</i>	---
<b>SM   Skin and Melanoma</b>				
<b>SMAJNIV</b>	Adjuvant Treatment of Resected Melanoma using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, instructions and contact info updated</i>
<b>SMAJNIV4</b>	Adjuvant Treatment of Resected Melanoma using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>SMAVALIPNI</b>	Treatment of Unresectable or Metastatic Melanoma using Alternative Dosing Regimen of Ipilimumab and Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<b>Maintenance PPPO</b> <i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects and contact info updated</i>
<b>SMAVIPNI</b>	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<b>Maintenance PPPO</b> <i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; treatment, side effects and contact info updated</i>
<b>SMAVNIV</b>	Treatment of Unresectable or Metastatic Melanoma using Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	<i>Nivolumab SC option added; side effects, instructions and contact info updated</i>
<b>SMAVNIV4</b>	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	<i>Nivolumab SC option added; precautions and contact information updated</i>	<i>Nivolumab SC option added</i>	

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a> <a href="mailto:BCCancerPPNAdmin@phsa.ca">BCCancerPPNAdmin@phsa.ca</a> <a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)  
 Jelena Mucovic, BScPharm (Assistant Editor)  
 Mário de Lemos, PharmD, MSc(Oncol)  
 Alina Gerrie, MD, MPH, FRCPC

Yuna Jang, RN  
 Michelle Lafreniere, BScN, RN  
 Alison Pow, BScPharm